Xenon Pharmaceuticals Inc.
CAFinancials
Valuation Metrics
Xenon Pharmaceuticals Inc.'s Market Cap is $3.62B. At end of 2025 it was $3.55B. Ranked #1579 of 3,116 in US market (top 51%), #553 of 1,472 on NASDAQ (top 38%), #91 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 34%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.62B | US#1,579/3,116 Sec#91/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-409M | US—/3,116 Sec—/265 |
| Total Assets | $1.30B | US#2,334/3,116 Sec#77/265 |
| Net Assets | $1.24B | US#1,613/3,116 Sec#52/265 |
| Employees | 364 | US#2,358/3,116 Sec#102/265 |
| Value | ||
| P/B | 2.91x | US#1,721/3,116 Sec#95/265 |
| P/S | 482.17x | US#2,973/3,116 Sec#192/265 |
| FCF Yield | -9.36% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -32.94% | US#2,581/3,116 Sec#121/265 |
| ROA | -31.58% | US#2,886/3,116 Sec#160/265 |
| Revenue Growth | -100.00% | US#2,726/3,116 Sec#182/265 |
| Financial Health | ||
| Debt Ratio | 4.30% | US#35/3,116 Sec#11/265 |
| Total Debt | $6M | US#2,865/3,116 Sec#209/265 |
| FCF | $-339M | US#2,863/3,116 Sec#239/265 |
| Cash | $120M | US#2,098/3,116 Sec#157/265 |
| Current Ratio | 21.02x | US#112/3,116 Sec#23/265 |
| Performance | ||
| 1Y Return | -12.33% | US#2,180/3,116 Sec#174/265 |
| 1M Return | 0.59% | US#1,773/3,116 Sec#120/265 |
| From 52W High | -48.51% | US#2,625/3,116 Sec#196/265 |
| 1Y MDD | -52.80% | US#2,507/3,116 Sec#176/265 |
| Trading | ||
| Volume | 1,094,255 shares | US#1,224/3,116 Sec#117/265 |
| Trading Value | $41M | US#1,297/3,116 Sec#94/265 |
| Per Share | ||
| EPS | $-4.23 | US—/3,116 Sec—/265 |
| BPS | $12.85 | US#1,649/3,116 Sec#54/265 |
Company Info
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.